Strata Oncology expands Strata PATH trial to eight Sarah Cannon Research Institute sites

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Sarah Cannon Research Institute joined Strata Oncology Inc.’s Precision Indications for Approved THerapies (NCT05097599) trial. Researchers will enroll patients at eight SCRI-affiliated sites including:

Florida Cancer Specialists (4 sites)Genesis Cancer and Blood Institute, Hot Springs, ARHematology Oncology Clinic, Baton Rouge, LATennessee Oncology, Chattanooga, TNZangmeister Cancer Center, Columbus, OH

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.​

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login